{"componentChunkName":"component---src-templates-post-template-js","path":"/react/best-cure-corona","result":{"data":{"post":{"title":"The best cure: which drugs may treat Coronavirus","date":null,"content":{"json":{"nodeType":"document","data":{},"content":[{"nodeType":"paragraph","content":[{"nodeType":"text","value":"Researches focus on two approaches to the treatment of the novel coronavirus. The first one is using the drugs, supplements and treatment methods currently available on the market that happen to provide antiviral effects. Another one is creating the vaccine, which may take a long time and money to happen.","marks":[],"data":{}}],"data":{}},{"nodeType":"paragraph","content":[{"nodeType":"text","value":"Let’s see what drugs are currently considered or developed by researchers.","marks":[],"data":{}}],"data":{}},{"nodeType":"heading-1","content":[{"nodeType":"text","value":"Chloroquine","marks":[],"data":{}}],"data":{}},{"nodeType":"paragraph","content":[{"nodeType":"text","value":"Chloroquine and less toxic hydroxychloroquine are used for the prevention and treatment of malaria. Due to their ability to reduce immune activity, these drugs are also used to treat autoimmune disorders, such as rheumatoid arthritis and lupus. In March 2020 the FDA issued an Emergency Use Authorisation that allows patients with COVID-19 to be treated using drugs with no clear evidence of their efficacy, approving limited emergency use for both drugs as a treatment for COVID-19. The medicines have quickly gotten into the media spotlight and were mentioned even by the President of the United States, Donald Trump. However, the European drugs regulator has claimed that while studies on both drugs are ongoing in COVID-19, they must not be used outside authorised uses. The use in clinical trials or nationally agreed protocols is allowed.","marks":[],"data":{}}],"data":{}},{"nodeType":"paragraph","content":[{"nodeType":"text","value":"Indeed, Chloroquine has shown some ","marks":[],"data":{}},{"nodeType":"hyperlink","content":[{"nodeType":"text","value":"antiviral effects","marks":[],"data":{}}],"data":{"uri":"https://medium.com/alphagreen/the-chance-for-a-breakthrough-can-chloroquine-fight-off-covid-19-341fc92c49fe"}},{"nodeType":"text","value":". It is able to change the pH of the parts in which viruses get into the cell, hindering the virus’ ability to reproduce. ","marks":[],"data":{}},{"nodeType":"hyperlink","content":[{"nodeType":"text","value":"A 2020 study","marks":[],"data":{}}],"data":{"uri":"https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa237/5801998"}},{"nodeType":"text","value":" by Chinese scientists with cultured cells infected by SARS-CoV-2 has shown that chloroquine administration may keep the virus from spreading.","marks":[],"data":{}}],"data":{}},{"nodeType":"paragraph","content":[{"nodeType":"text","value":"The International Journal of Antimicrobial Agents Meanwhile has published the results of a small-scale study evaluating the effectiveness of antimalarial drugs, such as Chloroquine and hydroxychloroquine against COVID-19. The combination of hydroxychloroquine and an antibiotic called azithromycin helped to reduce both the duration and symptoms of COVID-19.","marks":[],"data":{}}],"data":{}},{"nodeType":"paragraph","content":[{"nodeType":"text","value":"Even though Chloroquine has been used for a long time as an antimalarial drug, it may cause severe side effects, including death, if taken incorrectly. Even if taken as intended, the medication can cause stomach distress or permanent damage to a vision. Healthcare providers are warned that the optimal dosing of the drug and duration of treatment for COVID-19 are unknown and instructed to control heart activity concerning potential drugs’ side effects.","marks":[],"data":{}}],"data":{}},{"nodeType":"paragraph","content":[{"nodeType":"text","value":"The promising results of studies with Chloroquine are considered the very first step that should lead to more complex clinical studies and competing peer studies to prove its effectiveness. Multiple clinical trials by government agencies and academic institutions are ongoing. Study results published in the International Journal of Antimicrobial Agents has found that the combination of hydroxychloroquine and antibiotic azithromycin (brand names Zithromax or Azithrocin) ","marks":[],"data":{}},{"nodeType":"hyperlink","content":[{"nodeType":"text","value":"might be effective","marks":[],"data":{}}],"data":{"uri":"https://www.mediterranee-infection.com/hydroxychloroquine-and-azithromycin-as-a-treatment-of-covid-19/"}},{"nodeType":"text","value":" in treating the COVID-19 coronavirus and shortening the duration of the virus in patients.","marks":[],"data":{}}],"data":{}},{"nodeType":"heading-1","content":[{"nodeType":"text","value":"Remdesivir","marks":[],"data":{}}],"data":{}},{"nodeType":"paragraph","content":[{"nodeType":"text","value":"Remdesivir is an antiviral drug developed by Gilead Sciences. Remdesivir is an analogue of adenosine; therefore, it can incorporate into emerging viral RNA chains and cause their premature termination. Remdesivir was used as a treatment for Ebola virus disease, Marburg virus infections, and single-stranded RNA viruses, including coronaviruses (including MERS and SARS viruses).","marks":[],"data":{}}],"data":{}},{"nodeType":"paragraph","content":[{"nodeType":"text","value":"Remdesivir can interfere with the RNA, needed for virus replication. In the body, it is metabolised into a nucleotide analogue that is similar to adenosine, the RNA essential building block. It weakens the ability of the virus to produce its new RNA copies by suppressing an enzyme called RNA-dependent RNA polymerase. That is especially effective against viruses that only use RNA as their genetic material, without the DNA stage. A 2020 study with the use of a clinical isolate of 2019-nCoV in vitro, has shown that Remdesivir might ","marks":[],"data":{}},{"nodeType":"hyperlink","content":[{"nodeType":"text","value":"inhibit virus infection","marks":[],"data":{}}],"data":{"uri":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7054408/"}},{"nodeType":"text","value":" efficiently in a human cell line. Therefore, Remdesivir can act as a broad-spectrum antiviral, which is useful for diseases caused by RNA viruses such as cold, influenza, and Covid-19.","marks":[],"data":{}}],"data":{}},{"nodeType":"paragraph","content":[{"nodeType":"text","value":"Gilead Sciences has announced clinical trials with plans to enrol up to 1000 patients and has also made the drug available for compassionate use in emergency cases. The European Union’s health regulator has not approved Remdesivir for COVID-19 but recommended it for compassionate use, including its use for clinical trials.","marks":[],"data":{}}],"data":{}},{"nodeType":"heading-1","content":[{"nodeType":"text","value":"Favilavir (Avigan, Favipiravir)","marks":[],"data":{}}],"data":{}},{"nodeType":"paragraph","content":[{"nodeType":"text","value":"Favilavir is an antiviral drug developed by Toyama Chemical, Fujifilm group of Japan, that has activity against RNA viruses. In animal studies, it has shown an effect against influenza viruses, yellow fever virus, West Nile virus, foot-and-mouth disease virus.","marks":[],"data":{}}],"data":{}},{"nodeType":"paragraph","content":[{"nodeType":"text","value":"Favilavir can selectively inhibit viral RNA-dependent RNA polymerase, an enzyme that activates the replication of RNA from an RNA template. It may also generate lethal RNA transversion mutations, creating a nonviable viral phenotype. In practical terms, it means that drugs may prevent patients with low or moderate viral load from becoming sicker.","marks":[],"data":{}}],"data":{}},{"nodeType":"paragraph","content":[{"nodeType":"text","value":"In February 2020 regulatory officials in China approved Favilavir as an investigational therapy for the use as a treatment for the COVID-19. The approval was based on the efficacy of the medicine against the infectious disease in clinical tests with 70 patients conducted in Shenzhen, Guangdong province. However, some minor effects had also been recorded. At present, the generic version of Faviliavir was being mass-produced in China and promoted with the label Avigan. However, further work on pharmacy and clinical pharmacology research is required. Despite the positive results of the clinical trials and mass production of the Favilavir, it should be approved by the FDA to be considered as an effective treatment medicine for coronavirus. Japan’s government is also waiting on the results of their own clinical trials before producing the drug on a mass scale domestically.","marks":[],"data":{}}],"data":{}},{"nodeType":"heading-1","content":[{"nodeType":"text","value":"Lopinavir-ritonavir (Kaletra)","marks":[],"data":{}}],"data":{}},{"nodeType":"paragraph","content":[{"nodeType":"text","value":"Lopinavir/ritonavir (LPV/r), known under the brand name Kaletra and others, is a medication for the treatment and prevention of HIV/AIDS. The drug was created by Abbott Laboratories (now Abbvie). It is generally used with other antiretroviral drugs to treat HIV-1 infection in adults and pediatric patients 14 days and older. Ritonavir enhances the effect of lopinavir, and the combination of two drugs significantly reduces the morbidity and mortality in patients with HIV / AIDS. LPV/r has been approved by the US Food and Drug Administration and in Europe.","marks":[],"data":{}}],"data":{}},{"nodeType":"paragraph","content":[{"nodeType":"text","value":"A 2004 study has shown that LPV/r might be a ","marks":[],"data":{}},{"nodeType":"hyperlink","content":[{"nodeType":"text","value":"promising treatment option","marks":[],"data":{}}],"data":{"uri":"https://thorax.bmj.com/content/59/3/252.long"}},{"nodeType":"text","value":" for COVID-19. In essence, patients treated with these drugs in combination with ribavirin had a decreasing viral load and rising peripheral lymphocyte count. Countries heavily affected by COVID-19, such as Italy, ","marks":[],"data":{}},{"nodeType":"hyperlink","content":[{"nodeType":"text","value":"were recommended","marks":[],"data":{}}],"data":{"uri":"https://drive.google.com/file/d/1eXE6espkYp6_k2XCyTf_6kgT6tFbnQjg/view"}},{"nodeType":"text","value":" the drug combination for the novel coronavirus treatment.","marks":[],"data":{}}],"data":{}},{"nodeType":"paragraph","content":[{"nodeType":"text","value":"There are numerous ongoing trials, evaluating the lopinavir-ritonavir effect on COVID-19. Two trials examined how the drug’s combination could act against pneumonia induced by COVID-19. ","marks":[],"data":{}},{"nodeType":"hyperlink","content":[{"nodeType":"text","value":"An ongoing randomised controlled trial","marks":[],"data":{}}],"data":{"uri":"https://clinicaltrials.gov/ct2/show/NCT04255017?draw=2"}},{"nodeType":"text","value":" from Tongji Hospital of lopinavir-ritonavir is testing abidol hydrochloride, oseltamivir and lopinavir/ritonavir in the treatment of viral pneumonia. Another study conducted in South Korea is investigating whether hydroxychloroquine or lopinavir/ritonavir can ","marks":[],"data":{}},{"nodeType":"hyperlink","content":[{"nodeType":"text","value":"reduce the viral load","marks":[],"data":{}}],"data":{"uri":"https://clinicaltrials.gov/ct2/show/NCT04307693"}},{"nodeType":"text","value":" from a respiratory specimen in COVID-19 patients with mild symptoms. The World Health Organization is conducting a multi-centre, adaptive, randomised, open clinical trial to ","marks":[],"data":{}},{"nodeType":"hyperlink","content":[{"nodeType":"text","value":"assess the safety and efficacy","marks":[],"data":{}}],"data":{"uri":"https://clinicaltrials.gov/ct2/show/NCT04321616?term=hydroxychloroquine&cond=Coronavirus&draw=2"}},{"nodeType":"text","value":" of hydroxychloroquine, remdesivir and standard of care in adult patients with COVID-19. However, a clinical trial published in the ","marks":[],"data":{}},{"nodeType":"hyperlink","content":[{"nodeType":"text","value":"New England Journal of Medicine","marks":[],"data":{}}],"data":{"uri":"https://www.nejm.org/doi/full/10.1056/NEJMoa2001282?query=TOC"}},{"nodeType":"text","value":" has shown that treatment with lopinavir-ritonavir brought no difference from standard care in the time to clinical improvement in patients with cases of severe COVID-19.","marks":[],"data":{}}],"data":{}},{"nodeType":"paragraph","content":[{"nodeType":"text","value":"Therefore, the current clinical trial in South Korea and the Tongji Hospital are expected to prove or refute the effectiveness of LPV/r against COVID-19.","marks":[],"data":{}}],"data":{}},{"nodeType":"paragraph","content":[{"nodeType":"text","value":"The most common adverse effects of lopinavir/ritonavir are diarrhoea and nausea. Other common adverse effects include asthenia, abdominal ","marks":[],"data":{}},{"nodeType":"hyperlink","content":[{"nodeType":"text","value":"pain","marks":[],"data":{}}],"data":{"uri":"https://alphagreen.io/cbd-marketplace/cbd-for-pain-and-injury.html"}},{"nodeType":"text","value":", headache, vomiting, and rash. People with structural heart diseases, preexisting conduction system abnormalities, cardiomyopathies or ischaemic heart disease should use these drugs with caution.","marks":[],"data":{}}],"data":{}},{"nodeType":"heading-1","content":[{"nodeType":"text","value":"Tocilizumab (Actemra)","marks":[],"data":{}}],"data":{}},{"nodeType":"paragraph","content":[{"nodeType":"text","value":"Tocilizumab is an immunosuppressive drug, developed by Hoffmann–La Roche and Chugai and mostly used for the treatment of systemic juvenile idiopathic arthritis and rheumatoid arthritis. It is sold under the trade names Actemra and RoActemra.","marks":[],"data":{}}],"data":{}},{"nodeType":"paragraph","content":[{"nodeType":"text","value":"A 2020 research from China has shown that Tocilizumab may be ","marks":[],"data":{}},{"nodeType":"hyperlink","content":[{"nodeType":"text","value":"an effective treatment","marks":[],"data":{}}],"data":{"uri":"http://www.chinaxiv.org/abs/202003.00026"}},{"nodeType":"text","value":" for patients diagnosed as severe or critical COVID-19. Within a few days, the treatment caused positive results: temperature and oxygen intake lowering, lung lesion opacity absorption, normalisation of lymphocytes and C-reactive protein level. No significant reactions were observed.","marks":[],"data":{}}],"data":{}},{"nodeType":"paragraph","content":[{"nodeType":"text","value":"Genentech from the Roche Group and the US Biomedical Advanced Research and Development Authority have launched a randomised, controlled trial (COVACTA) to evaluate the safety and efficacy of intravenous Actemra (Tocilizumab) and care standards in adult patients with severe COVID-19 pneumonia.","marks":[],"data":{}}],"data":{}},{"nodeType":"paragraph","content":[{"nodeType":"text","value":"Actemra (Tocilizumab) has been approved in China for the treatment of patients with the COVID-19, who have also developed severe lung damage and have high levels of IL-6 in the blood. The studies have suggested that an elevated level of IL-6, a biomarker for inflammation and high-level immune response, may be lethal for people with community-acquired pneumonia.","marks":[],"data":{}}],"data":{}},{"nodeType":"paragraph","content":[{"nodeType":"text","value":"The mechanism of Tocilizumab includes an interruption of the process of ‘cytokine release syndrome’ (CRS), a complication in the form of severe inflammatory response.","marks":[],"data":{}}],"data":{}},{"nodeType":"paragraph","content":[{"nodeType":"text","value":"However, Actemra is not currently approved for this use by the FDA. The most frequent adverse effects observed in clinical trials are upper respiratory tract infections, common cold, headache, high blood pressure and total cholesterol levels.","marks":[],"data":{}}],"data":{}}]}},"image":{"fluid":{"base64":"data:image/jpeg;base64,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","aspectRatio":1.5005359056806002,"src":"//images.ctfassets.net/k6zu3w7d9zcg/4sQ72uIsxHYMj6qEFnCs7t/30d236a0a66a0b25a646ba95d13556cd/cure.jpeg?w=2048&q=50","srcSet":"//images.ctfassets.net/k6zu3w7d9zcg/4sQ72uIsxHYMj6qEFnCs7t/30d236a0a66a0b25a646ba95d13556cd/cure.jpeg?w=512&h=341&q=50 512w,\n//images.ctfassets.net/k6zu3w7d9zcg/4sQ72uIsxHYMj6qEFnCs7t/30d236a0a66a0b25a646ba95d13556cd/cure.jpeg?w=1024&h=682&q=50 1024w,\n//images.ctfassets.net/k6zu3w7d9zcg/4sQ72uIsxHYMj6qEFnCs7t/30d236a0a66a0b25a646ba95d13556cd/cure.jpeg?w=1400&h=933&q=50 1400w","sizes":"(max-width: 2048px) 100vw, 2048px"}}}},"pageContext":{"id":"7N2ZkgtrKQqPgnL2Mk2xVa"}}}